Revive Adds First-of-its-Kind Neighborhood Report Feature to Vision AI, Transforming Real Estate Valuations With AI-Driven Condition Analysis
IRVINE, Calif., May 14, 2024 /PRNewswire/ -- Most homeowners understand that updating and renovating their home could help them earn more money at its sale, but because "seeing is believing," they mi
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
Revive Therapeutics (RVV.CN), a specialty life sciences company, on Thursday announced that the U.S. Food and Drug Administration has assigned it a meeting date of June 7. Revive had requested a meeti
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
Mind Medicine Sends Psychedelic Stocks Higher After FDA Status for LSD Formulation
Oregon House Passes Bill to End Hard Drug Decriminalization
There are many factors in setting drug policy, which often center around the benefits or detriments to a society and its economy.
Press Release: Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO
Psychedelic Stocks Gain After FDA Priority Review for MDMA Therapy
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- REVIVE
Revive Therapeutics Announces Offering of up to $3 Million
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- REVIVE
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure With Defence Research and Development Canada
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
TORONTO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
Revive Therapeutics Collaborates With Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
TORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
Revive Therapeutics Enters Into Worldwide Exclusive Agreement With Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
Potential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID TORONTO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company")
Revive Therapeutics Enters Into Agreement With Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
TORONTO, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of
No Data